)
Visual22 Oct 2025
Epiroc's cash spent on M&A
Affimed (AFMD) investor relations material
Affimed Leerink’s Global Healthcare Conference 2025 summary
Complete event summary combining all related documents: earnings call transcript, report, and slide presentation.Leerink’s Global Healthcare Conference 2025 summary11 Mar, 2025
Executive leadership and company strategy
Sean Nilan, new CEO of Affimed, brings extensive experience in biotech leadership, fundraising, and clinical development, having previously led Elevation Oncology and Forbio.
Affimed is prioritizing its pipeline based on investor and partner feedback, focusing on programs with the highest commercial potential.
Pipeline prioritization will be influenced by the next financing round, with AFM24 and AFM28 receiving the most interest.
The company is considering deprioritizing programs with lower commercial potential, such as the asymptomatic program.
Investor and partner interests are aligned, with both groups focusing on late-phase, high-potential assets.
Clinical program updates and data readouts
AFM24, an EGFR/CD16A innate cell engager, has shown encouraging monotherapy and combination activity in non-small cell lung cancer (NSCLC), with response rates of 21-24% and median PFS of 5.6 months in both EGFR wild-type and mutant cohorts.
Higher exposure to AFM24 correlates with improved efficacy; a new 720mg cohort is planned, aiming for >30% ORR and >7 months median PFS.
AFM28, a CD123 NK cell engager for AML, demonstrated a 40% composite CR rate and response durations of 2.5–6.5 months at the 300mg dose, surpassing recent regulatory benchmarks.
Dose escalation for AFM28 continues, with data from the next cohort expected in 6–9 months.
The company is optimizing trial design by excluding prior taxane exposure in the next AFM24 cohort to enrich for better PFS outcomes.
Partnering, commercial, and regulatory considerations
The partnership with Artiva for the asymptomatic program introduces economic complexities, but combination therapy is seen as necessary for durable responses.
Expanding into relapsed/refractory PTCL is viewed as key to unlocking greater commercial potential for the asymptomatic program.
Registration paths for AFM24 in NSCLC will require Phase 3 trials versus docetaxel, with regulatory discussions on contribution of parts pending.
NK cell engager approaches are differentiated by a wider therapeutic index and reduced toxicity compared to T-cell engagers and other modalities.
Commercial viability and scalability are central to development decisions, especially in transitioning from academic to industry-grade NK cell sources.
How will financing dictate pipeline choices?
When will PTCL enrollment begin for Asymptomig?
Why did prior AFM24 PD modeling fall short?
Partial view of Summaries dataset, powered by Quartr API
Research faster. Power your platform.
The essential earnings season companion
The #1 app for live earnings calls, transcripts, analyst estimates, and more. All for free.
Live calls and transcripts
Listen to earnings calls, CMDs, investor conferences, and more – with a podcast-like experience.
Find what you need faster
Search for any keyword across all transcripts simultaneously.
Easily store key findings
Capturing important takeaways is as simple as it gets. Even during your lunch run or commute.
Your watchlist. Your dashboard.
Follow the companies that matter to you. Get a personalized feed with real-time updates.
Be the first to know
Set keyword alerts for any company, product, or competitor. Get notified the moment they're mentioned.
Consensus estimates
Access analyst consensus estimates, valuation multiples, and revenue segments splits.
All IR material in one place
The easiest way to stay updated during earnings season.
Global coverage
All events from public companies. Live and recorded.
Just click and listen
No webcast links. No manual registrations.
excellent app, it gives me free access to company earnings calls and annual reports. I also love the convenience of calls being available offline so I can listen in whilst doing other things and even when internet or WiFi isn't available.
)
Leroy DaleyApp Store
One of the very few apps you could call perfect. If something was to add to it, maybe the share price of the company when you search for it, but it's already excellent.
)
Eferix Drawings Google Play
This is genuinely one of the cleanest and fastest finance apps out there to track the market.
anuj283App Store
excellent app, it gives me free access to company earnings calls and annual reports. I also love the convenience of calls being available offline so I can listen in whilst doing other things and even when internet or WiFi isn't available.
Leroy DaleyApp Store
One of the very few apps you could call perfect. If something was to add to it, maybe the share price of the company when you search for it, but it's already excellent.
Eferix Drawings Google Play
This is genuinely one of the cleanest and fastest finance apps out there to track the market.
anuj283App Store
I can't remember the last time an app had such a positive impact on my investment process.
)
@ankurshah47_ x.com
Love the app! Quartr makes it really easy to keep track of earnings calls. It also includes the reports and slides to make it easier to follow along.
Amina0781App Store
Quartr is amazing, no way around it. It is the best right now for earnings calls, presentations, and the like.
@theshortbearx.com
I can't remember the last time an app had such a positive impact on my investment process.
@ankurshah47_ x.com
Love the app! Quartr makes it really easy to keep track of earnings calls. It also includes the reports and slides to make it easier to follow along.
Amina0781App Store
Quartr is amazing, no way around it. It is the best right now for earnings calls, presentations, and the like.
@theshortbearx.com
)
)
Frequently asked questions
Affimed N.V., a clinical-stage biopharmaceutical company, focuses on discovering and developing cancer immunotherapies in the United States, Europe, and Germany. The company operates through two segments, Affimed Therapeutics, and Redoxa GmbH. It develops therapies based on its proprietary TandAb platform to unleash the innate power of the immune system by harnessing the functionality of natural killer cells and T-cells for the treatment of cancer.
The company has strategic partnerships with Genentech Inc.; Merck KGaA and Pfizer Inc.; Novartis Institutes for BioMedical Research, Inc.; Celgene Corporation; Bayer Pharma AG; MorphoSys AG; Incyte Corporation; Amgen Inc.; Hoffmann-La Roche ltd; Sanofi S.A.; and Bristol-Myers Squibb Company. Affimed N.V. was founded in 2000 and is headquartered in Heidelberg, Germany
Quartr provides global coverage of all investor relation material from public companies.
Mobile app: Research anytime, anywhere with the #1 app for live earnings calls, transcripts, analyst estimates, and more. All for free.
Desktop (Quartr Pro): The leading platform for qualitative research, used daily by top firms and financial institutions.
Quartr API: Build custom solutions powered by live earnings calls, live transcripts, filings and reports, slide presentations, and more.
Yes, the Quartr mobile app is free on both iOS and Android.
Yes. Quartr provides global, industry-leading live coverage of company events such as regular earnings calls, capital markets days, M&A announcements, and investor conferences. Live with zero delays. Just click and listen.
Yes, capturing important takeaways is as simple as it gets. Even during your lunch run or commute.
Yes. Follow the companies that matter to you. Get a personalized feed with real-time updates, a tailored earnings calendar, and instant alerts when earnings calls go live.
Yes. Set keyword alerts for any company, product, or competitor. Get notified the moment they're mentioned, regardless of who's talking.
Explore our global coverage